A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDUnderstanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular functionTreatment of adults with attention-deficit/hyperactivity disorderTreatment of adults with attention-deficit/hyperactivity disorderImmediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesMethylphenidate use in pregnancy and lactation: a systematic review of evidenceMeta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adultsAssociations of sleep disturbance with ADHD: implications for treatmentEfficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsPharmacological treatment of adult ADHD in EuropeSafety of therapeutic methylphenidate in adults: a systematic review of the evidenceAttention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementTipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary studyCardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort studyThe social and cultural construction of psychiatric knowledge: an analysis of NICE guidelines on depression and ADHD.Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorderImaging dopamine neurotransmission in live human brain.Health state utilities associated with adult attention-deficit/hyperactivity disorder.Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.Aortic dissection in young adults who abuse amphetamines.Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.Methylphenidate off-label use and safety.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsDo prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trialAdult ADHD Medications and Their Cardiovascular ImplicationsClinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidateMultiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.Mindfulness based cognitive therapy versus treatment as usual in adults with attention deficit hyperactivity disorder (ADHD).Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.Attention-Deficit/Hyperactivity Disorder Symptom Profiles in Medication-Treated Adults Entering a Psychosocial Treatment Program.Osmotic release oral system methylphenidate prevents weight gain during a smoking-cessation attempt in adults with ADHDRisk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder.
P2860
Q21260332-3DF09BBD-F06D-4F48-88DE-6A14B2EACC35Q22252308-E9271A32-C241-489C-982F-D90A093EE018Q24642937-F931926E-AD6B-4396-8FC2-653B68DBB96AQ24644586-8245600E-B39E-41A2-9113-DC27BB5EA57AQ26471999-7D620EC2-9A75-417B-AC0E-A9E502599EF6Q26822392-E68DF65F-BB90-4B1B-9E51-172D7FD40CABQ26851791-9B92FA13-BB02-45DF-8D05-E9A6F465072AQ26858868-968F9C8B-CF85-4E62-9736-4F01CA800771Q27027062-10986691-73FC-403D-846C-6879A2998E3CQ28246506-17F3ADE6-4FFD-415B-846C-C8BFE3C99672Q28247634-5A78CBA7-8C3A-4477-92C2-F77569347DF1Q28282264-E550DB49-5E4A-430F-998F-9BA98DAB9E47Q28295525-3C0CC780-D4EA-4362-BC09-467D9E4B6FB6Q28307232-032DB3A3-2EA1-4F0B-A8D8-4BC521EB54F6Q28729087-817AF1DD-BE2D-4F47-8907-E0C869E56AC9Q30428292-33506CA1-F0AB-44D4-945A-999BD3FEB3ECQ30449130-CD32B754-13CD-4666-9060-68B24087AA39Q33299018-0464AB76-D401-4A37-8C7F-52F217CE90E8Q33858606-7345645A-16C8-4101-943E-60D773280AA8Q33944593-7E86259C-D3F0-4B2E-BA92-2A0BA36A1A2CQ34011677-7751F74B-D65B-41A7-A7E9-BBE268A7C062Q34045097-0BF64415-03A2-4BAE-90C1-B5F1791D5935Q34076770-62F75513-660C-4A74-B772-3DBBC0207B25Q34085116-F9C42044-81FA-41BA-B111-EAB88B95A648Q34172165-E061FC29-B9A7-4270-9662-F4474C4A66F2Q34220004-665057DA-B39B-435B-AA5C-4652AFEE067CQ34280107-F217DBF4-DE46-41EA-B0A1-EDE2F2555CF1Q34362939-ECD850C4-E576-4CC2-B4EC-E81BB46333F1Q34481951-B542AE18-1086-402E-A919-5E2ABEC57EE5Q34539026-54D7CC39-7BCA-45E5-BBE4-403B3837651AQ34565497-2A18C296-89FE-4621-A29D-93907F1899C6Q35057288-B45A35B1-09B8-4A48-AE92-2F5C1E670D28Q35151922-7ECBC3DC-D850-4FF2-AEDB-97A25F44CA3DQ35579008-77F605FD-F28F-460C-AEB0-A7BC409C163CQ35755924-323F15E2-F8A2-4A56-9FBC-77DB98FD9D5EQ35776563-46FA4E40-BB11-4365-BA8C-F4EE7874FC9CQ35833310-6B33AD6E-5F5A-4FAF-80DA-C43F678BBD28Q36165505-7C411397-289E-4288-B535-8211B6A219B7Q36534998-C2DF245A-F6C4-4EEE-B800-0F82AD2A84BEQ36567686-237E450C-7652-4F82-A761-EF4563C7AB11
P2860
A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A randomized, placebo-controll ...... eficit/hyperactivity disorder.
@en
A randomized, placebo-controll ...... eficit/hyperactivity disorder.
@nl
type
label
A randomized, placebo-controll ...... eficit/hyperactivity disorder.
@en
A randomized, placebo-controll ...... eficit/hyperactivity disorder.
@nl
prefLabel
A randomized, placebo-controll ...... eficit/hyperactivity disorder.
@en
A randomized, placebo-controll ...... eficit/hyperactivity disorder.
@nl
P2093
P1476
A randomized, placebo-controll ...... eficit/hyperactivity disorder.
@en
P2093
Craig Surman
Megan Aleardi
Meghan Dougherty
Paul Hammerness
Robert Doyle
Stephanie Dunkel
Theresa Harpold
Thomas Spencer
P304
P356
10.1016/J.BIOPSYCH.2005.09.011
P407
P577
2005-12-20T00:00:00Z